Barings’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Barings’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-199,390	Closed	-$10.8M	–	965
2017 Q4	$10.8M	Buy	199,390 +107,300	+117%	+$5.87M	0.14%	117
2017 Q3	$5.26M	Buy	92,090 +28,015	+44%	+$1.64M	0.09%	135
2017 Q2	$3.85M	Sell	64,075 -4,261	-6%	-$243K	0.11%	161
2017 Q1	$3.72M	Buy	+68,336	New	+$3.37M	0.04%	409

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Barings's BIVV Position: Q1 2018 in Review

Barings sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 199,390 shares — an estimated $10.8M sold.

Barings first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $10.8M in Q4 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Barings reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Barings sold 199,390 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $10.8M.
Barings first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Barings's Bioverativ Inc. Common Stock position peaked at $10.8M in Q4 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Barings's 13F filing for Q1 2018, filed 4 May 2018.